Influenza revenues rose 112 percent due to an especially long and severe respiratory disease season, dominated by a virulent H3N2 strain of influenza.
While point-of-care molecular testing of patients with respiratory illness wasn't associated with lower antibiotic use, patients tested had shorter drug courses.
The Liat point of care system system has launched with four assays, including three respiratory tests and a novel test for Clostridium difficile.
Genetic analysis finds that the bird flu strain found on a Tennessee chicken farm differs from one linked to multiple deaths in China, Reuters reports.
In PNAS this week: flu susceptibility and Y chromosome variation in mice, deletion tied to epilepsy in dog breed, and more.
The tests are twice as fast as the firm's Xpert line and run on Cepheid's flagship GeneXpert system.
The White House Office of Science and Technology Policy has new guidelines for potential pandemic pathogen research, according to ScienceInsider.
The company said it expects revenues of $52 million to $53 million for the quarter, compared to analysts' average estimate of $63.1 million.
The firm also announced that it plans to expand its RAS biomarker testing collaboration with Amgen in Europe.
The bank said that although it is forecasting a 17 percent stronger flu season this year, Quidel's influenza sales are only likely to rise 10 percent.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.